Symbols / NVAX
NVAX Chart
About
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.54B |
| Enterprise Value | 1.03B | Income | 341.74M | Sales | 1.06B |
| Book/sh | -0.96 | Cash/sh | 4.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 952 | IPO | — |
| P/E | 4.71 | Forward P/E | -27.31 | PEG | — |
| P/S | 1.44 | P/B | -9.81 | P/C | — |
| EV/EBITDA | 2.27 | EV/Sales | 0.96 | Quick Ratio | 1.85 |
| Current Ratio | 2.27 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 2.01 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | -16.60% | Earnings | 2026-02-26 | ROA | 18.01% |
| ROE | — | ROIC | — | Gross Margin | 59.42% |
| Oper. Margin | -112.68% | Profit Margin | 32.10% | Shs Outstand | 162.50M |
| Shs Float | 140.20M | Short Float | 31.61% | Short Ratio | 8.37 |
| Short Interest | — | 52W High | 10.64 | 52W Low | 5.01 |
| Beta | 2.58 | Avg Volume | 4.32M | Volume | 2.92M |
| Target Price | $13.00 | Recom | Buy | Prev Close | $9.36 |
| Price | $9.46 | Change | 1.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.00
Mean price target
2. Current target
$9.46
Latest analyst target
3. DCF / Fair value
$-50.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.46
Low
$6.00
High
$25.00
Mean
$13.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-20 | reit | BTIG | Buy → Buy | $19 |
| 2025-11-18 | main | JP Morgan | Underweight → Underweight | $6 |
| 2025-11-10 | reit | B. Riley Securities | Buy → Buy | $16 |
| 2025-11-04 | main | TD Cowen | Hold → Hold | $7 |
| 2025-10-24 | init | Cantor Fitzgerald | — → Overweight | $18 |
| 2025-10-23 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-08-20 | down | B of A Securities | Neutral → Underperform | $7 |
| 2025-07-22 | main | B of A Securities | Neutral → Neutral | $9 |
| 2025-06-17 | init | Citigroup | — → Sell | $6 |
| 2025-05-09 | main | JP Morgan | Underweight → Underweight | $7 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2024-08-12 | reit | B. Riley Securities | Buy → Buy | $23 |
| 2024-08-12 | main | JP Morgan | Underweight → Underweight | $9 |
| 2024-08-02 | main | B. Riley Securities | Buy → Buy | $25 |
| 2024-07-30 | down | JP Morgan | Neutral → Underweight | $8 |
| 2024-06-14 | main | B of A Securities | Neutral → Neutral | $18 |
| 2024-05-23 | main | B. Riley Securities | Buy → Buy | $29 |
| 2024-05-13 | main | TD Cowen | Hold → Hold | $10 |
- Novavax (NVAX) Q4 Earnings Report Preview: What To Look For - TradingView Wed, 25 Feb 2026 11
- Assessing Novavax (NVAX) Valuation After Recent Share Price Momentum And Mixed Long Term Returns - simplywall.st ue, 24 Feb 2026 14
- Novavax (NVAX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Mon, 23 Feb 2026 17
- Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits ue, 24 Feb 2026 17
- How Novavax Inc. (NVAX) Affects Rotational Strategy Timing - Stock Traders Daily hu, 19 Feb 2026 03
- Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance hu, 22 Jan 2026 08
- BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets - Yahoo Finance Sat, 31 Jan 2026 08
- Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now? - Yahoo Finance ue, 17 Feb 2026 14
- Why Novavax (NVAX) Dipped More Than Broader Market Today - Yahoo Finance ue, 03 Feb 2026 08
- Novavax (NVAX) Stock Trades Up, Here Is Why - Yahoo Finance Fri, 02 Jan 2026 08
- Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance ue, 28 Oct 2025 07
- Assessing Novavax (NVAX) Valuation After Recent Share Price Momentum And Partnership Shifts - Yahoo Finance Fri, 13 Feb 2026 08
- Novavax (NVAX): Exploring Valuation After Prolonged Share Price Weakness - Yahoo Finance Wed, 03 Dec 2025 08
- Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance Mon, 08 Dec 2025 08
- Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance hu, 22 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 83197 | — | — | JACOBS JOHN C | Chief Executive Officer | — | 2026-01-23 00:00:00 | D | nan |
| 1 | 41899 | — | — | CASEY MARK J | Officer | — | 2025-12-11 00:00:00 | D | nan |
| 2 | 14257 | — | — | DRAGHIA-AKLI RUXANDRA | Officer | — | 2025-11-11 00:00:00 | D | nan |
| 3 | 3800 | — | — | RODGERS RICHARD J. | Director | — | 2025-10-29 00:00:00 | D | nan |
| 4 | 10420 | — | — | RODGERS RICHARD J. | Director | — | 2025-06-12 00:00:00 | D | nan |
| 5 | 10420 | — | — | ALTON GREGG H | Director | — | 2025-06-12 00:00:00 | D | nan |
| 6 | 10420 | — | — | MOTT DAVID M | Director | — | 2025-06-12 00:00:00 | D | nan |
| 7 | 10420 | — | — | MCGLYNN MARGARET G | Director | — | 2025-06-12 00:00:00 | D | nan |
| 8 | 10420 | — | — | DOUGLAS RICHARD H | Director | — | 2025-06-12 00:00:00 | D | nan |
| 9 | 10420 | — | — | KING RACHEL K | Director | — | 2025-06-12 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 10.91M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -159.99M | -487.39M | -604.71M | -1.68B |
| TotalUnusualItems | 51.95M | 0.00 | 0.00 | 1.36M |
| TotalUnusualItemsExcludingGoodwill | 51.95M | 0.00 | 0.00 | 1.36M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -187.50M | -545.06M | -657.94M | -1.74B |
| ReconciledDepreciation | 48.50M | 41.23M | 29.05M | 12.66M |
| ReconciledCostOfRevenue | 202.74M | 343.77M | 902.64M | 0.00 |
| EBITDA | -108.04M | -487.39M | -604.71M | -1.68B |
| EBIT | -156.54M | -528.62M | -633.77M | -1.69B |
| NetInterestIncome | -20.07M | -14.42M | -19.88M | -21.13M |
| InterestExpense | 20.07M | 14.42M | 19.88M | 21.13M |
| NormalizedIncome | -228.54M | -545.06M | -657.94M | -1.74B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -187.50M | -545.06M | -657.94M | -1.74B |
| TotalExpenses | 931.09M | 1.12B | 2.24B | 1.88B |
| TotalOperatingIncomeAsReported | -248.93M | -566.51M | -644.74M | -1.69B |
| DilutedAverageShares | 152.19M | 100.77M | 78.18M | 74.40M |
| BasicAverageShares | 152.19M | 100.77M | 78.18M | 74.40M |
| DilutedEPS | -1.23 | -5.41 | -8.42 | -23.44 |
| BasicEPS | -1.23 | -5.41 | -8.42 | -23.44 |
| DilutedNIAvailtoComStockholders | -187.50M | -545.06M | -657.94M | -1.74B |
| NetIncomeCommonStockholders | -187.50M | -545.06M | -657.94M | -1.74B |
| NetIncome | -187.50M | -545.06M | -657.94M | -1.74B |
| NetIncomeIncludingNoncontrollingInterests | -187.50M | -545.06M | -657.94M | -1.74B |
| NetIncomeContinuousOperations | -187.50M | -545.06M | -657.94M | -1.74B |
| TaxProvision | 10.88M | 2.03M | 4.29M | 29.21M |
| PretaxIncome | -176.62M | -543.03M | -653.65M | -1.71B |
| OtherIncomeExpense | 92.39M | 37.90M | 10.97M | -6.83M |
| OtherNonOperatingIncomeExpenses | 40.44M | 37.90M | 10.97M | -6.83M |
| SpecialIncomeCharges | 51.95M | 0.00 | 0.00 | 0.00 |
| GainOnSaleOfPPE | 51.95M | 0.00 | 0.00 | 0.00 |
| GainOnSaleOfSecurity | 1.36M | |||
| NetNonOperatingInterestIncomeExpense | -20.07M | -14.42M | -19.88M | -21.13M |
| InterestExpenseNonOperating | 20.07M | 14.42M | 19.88M | 21.13M |
| OperatingIncome | -248.93M | -566.51M | -644.74M | -1.69B |
| OperatingExpense | 728.35M | 779.12M | 1.34B | 1.88B |
| OtherOperatingExpenses | -427.32M | -382.92M | -948.71M | |
| ResearchAndDevelopment | 391.17M | 737.50M | 1.24B | 2.53B |
| SellingGeneralAndAdministration | 337.19M | 468.95M | 488.69M | 298.36M |
| GeneralAndAdministrativeExpense | 488.69M | 298.36M | ||
| OtherGandA | 488.69M | 298.36M | ||
| GrossProfit | 479.42M | 212.61M | 696.31M | 197.58M |
| CostOfRevenue | 202.74M | 343.77M | 902.64M | 0.00 |
| TotalRevenue | 682.16M | 556.38M | 1.60B | 197.58M |
| OperatingRevenue | 682.16M | 556.38M | 1.60B | 197.58M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.52M | 1.00M | 766.63K | 591.98K |
| OrdinarySharesNumber | 160.42M | 139.51M | 86.04M | 75.84M |
| ShareIssued | 161.94M | 140.51M | 86.81M | 76.43M |
| TotalDebt | 230.42M | 229.08M | 549.78M | 453.99M |
| TangibleBookValue | -731.32M | -844.38M | -760.41M | -483.15M |
| InvestedCapital | -454.16M | -548.91M | -142.73M | -28.21M |
| WorkingCapital | -25.47M | -491.25M | -756.55M | -235.20M |
| NetTangibleAssets | -731.32M | -844.38M | -760.41M | -483.15M |
| CapitalLeaseObligations | 60.73M | 61.06M | 58.43M | 130.53M |
| CommonStockEquity | -623.84M | -716.93M | -634.08M | -351.67M |
| TotalCapitalization | -454.16M | -548.91M | -467.61M | -28.21M |
| TotalEquityGrossMinorityInterest | -623.84M | -716.93M | -634.08M | -351.67M |
| StockholdersEquity | -623.84M | -716.93M | -634.08M | -351.67M |
| GainsLossesNotAffectingRetainedEarnings | -22.56M | 2.72M | -6.38M | -1.35M |
| OtherEquityAdjustments | -22.56M | 2.72M | -6.38M | -1.35M |
| TreasuryStock | 95.85M | 92.27M | 90.66M | 85.10M |
| RetainedEarnings | -5.01B | -4.82B | -4.28B | -3.62B |
| AdditionalPaidInCapital | 4.50B | 4.19B | 3.74B | 3.35B |
| CapitalStock | 1.62M | 1.41M | 868.00K | 764.00K |
| CommonStock | 1.62M | 1.41M | 868.00K | 764.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 2.18B | 2.51B | 2.89B | 2.93B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.03B | 879.28M | 432.81M | 538.11M |
| OtherNonCurrentLiabilities | 359.61M | 33.13M | 55.70M | 42.12M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 446.82M | 622.21M | 179.41M | 172.53M |
| NonCurrentDeferredRevenue | 446.82M | 622.21M | 179.41M | 172.53M |
| LongTermDebtAndCapitalLeaseObligation | 223.41M | 223.94M | 197.70M | 323.46M |
| LongTermCapitalLeaseObligation | 53.73M | 55.92M | 31.24M | 0.00 |
| LongTermDebt | 169.68M | 168.02M | 166.47M | 323.46M |
| CurrentLiabilities | 1.15B | 1.64B | 2.46B | 2.39B |
| OtherCurrentLiabilities | 219.60M | 861.41M | 930.05M | 36.06M |
| CurrentDeferredLiabilities | 675.07M | 241.31M | 370.14M | 1.42B |
| CurrentDeferredRevenue | 675.07M | 241.31M | 370.14M | 1.42B |
| CurrentDebtAndCapitalLeaseObligation | 7.01M | 5.14M | 352.08M | 130.53M |
| CurrentCapitalLeaseObligation | 7.01M | 5.14M | 27.20M | 130.53M |
| CurrentDebt | 324.88M | |||
| OtherCurrentBorrowings | 324.88M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 60.35M | 55.95M | 52.57M | 38.42M |
| PayablesAndAccruedExpenses | 192.39M | 471.33M | 755.11M | 762.36M |
| CurrentAccruedExpenses | 150.81M | 338.72M | 538.59M | 635.31M |
| Payables | 41.58M | 132.61M | 216.52M | 127.05M |
| AccountsPayable | 41.58M | 132.61M | 216.52M | 127.05M |
| TotalAssets | 1.56B | 1.80B | 2.26B | 2.58B |
| TotalNonCurrentAssets | 431.48M | 653.60M | 555.29M | 421.63M |
| OtherNonCurrentAssets | 24.00M | 35.16M | 28.47M | 24.29M |
| GoodwillAndOtherIntangibleAssets | 107.48M | 127.45M | 126.33M | 131.48M |
| OtherIntangibleAssets | 4.77M | |||
| Goodwill | 107.48M | 127.45M | 126.33M | 131.48M |
| NetPPE | 300.00M | 490.99M | 400.49M | 265.86M |
| AccumulatedDepreciation | -49.16M | -74.97M | -47.29M | -25.80M |
| GrossPPE | 349.15M | 565.96M | 447.78M | 291.66M |
| Leases | 66.89M | 48.31M | 18.89M | 10.28M |
| ConstructionInProgress | 39.51M | 76.16M | 81.57M | 35.11M |
| OtherProperties | 161.59M | 185.22M | 106.24M | 40.12M |
| MachineryFurnitureEquipment | 66.23M | 153.36M | 139.74M | 122.61M |
| LandAndImprovements | 14.95M | 102.92M | 101.34M | 83.53M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.13B | 1.14B | 1.70B | 2.16B |
| OtherCurrentAssets | 21.89M | 155.73M | 76.37M | 44.62M |
| RestrictedCash | 10.63M | 10.42M | 10.30M | 11.49M |
| PrepaidAssets | 56.28M | 70.30M | 160.77M | 120.03M |
| Inventory | 8.75M | 41.70M | 36.68M | 8.87M |
| FinishedGoods | 1.76M | 27.69M | 1.36M | 0.00 |
| WorkInProcess | 4.90M | 7.39M | 21.41M | 0.00 |
| RawMaterials | 2.09M | 6.61M | 13.91M | 8.87M |
| Receivables | 108.28M | 297.24M | 82.38M | 454.99M |
| AccountsReceivable | 108.28M | 297.24M | 82.38M | 454.99M |
| CashCashEquivalentsAndShortTermInvestments | 923.12M | 568.50M | 1.34B | 1.52B |
| OtherShortTermInvestments | 392.89M | 0.00 | 0.00 | |
| CashAndCashEquivalents | 530.23M | 568.50M | 1.34B | 1.52B |
| CashEquivalents | 1.42B | |||
| CashFinancial | 96.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -101.90M | -772.77M | -508.92M | 265.46M |
| RepaymentOfDebt | -3.99M | -352.35M | -93.59M | -127.91M |
| IssuanceOfDebt | 0.00 | 0.00 | 175.25M | 0.00 |
| IssuanceOfCapitalStock | 263.27M | 360.24M | 249.23M | 564.86M |
| CapitalExpenditure | -14.64M | -58.81M | -92.98M | -57.49M |
| InterestPaidSupplementalData | 17.57M | 17.35M | 18.04M | 19.43M |
| IncomeTaxPaidSupplementalData | 949.00K | 190.00K | 17.98M | 12.61M |
| EndCashPosition | 545.29M | 583.81M | 1.35B | 1.53B |
| BeginningCashPosition | 583.81M | 1.35B | 1.53B | 648.74M |
| EffectOfExchangeRateChanges | -7.80M | 3.27M | 4.52M | -5.29M |
| ChangesInCash | -30.72M | -768.31M | -183.93M | 884.81M |
| FinancingCashFlow | 260.58M | 4.47M | 324.99M | 461.71M |
| CashFlowFromContinuingFinancingActivities | 260.58M | 4.47M | 324.99M | 461.71M |
| NetOtherFinancingCharges | -3.59M | -5.26M | ||
| ProceedsFromStockOptionExercised | 1.30M | 159.00K | -639.00K | 24.76M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 263.27M | 360.24M | 249.23M | 564.86M |
| CommonStockIssuance | 263.27M | 360.24M | 249.23M | 564.86M |
| NetIssuancePaymentsOfDebt | -3.99M | -352.35M | 81.66M | -127.91M |
| NetLongTermDebtIssuance | -3.99M | -352.35M | 81.66M | -127.91M |
| LongTermDebtPayments | -3.99M | -352.35M | -93.59M | -127.91M |
| LongTermDebtIssuance | 0.00 | 0.00 | 175.25M | 0.00 |
| InvestingCashFlow | -204.04M | -58.81M | -92.98M | 100.15M |
| CashFlowFromContinuingInvestingActivities | -204.04M | -58.81M | -92.98M | 100.15M |
| NetOtherInvestingChanges | 192.64M | |||
| NetInvestmentPurchaseAndSale | -382.04M | 0.00 | 0.00 | 157.64M |
| SaleOfInvestment | 443.55M | 0.00 | 0.00 | 159.81M |
| PurchaseOfInvestment | -825.59M | 0.00 | 0.00 | -2.17M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfBusiness | 0.00 | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -1.58M | -5.04M | -3.93M | -2.98M |
| PurchaseOfIntangibles | -3.93M | -2.98M | ||
| CapitalExpenditureReported | -13.06M | -53.77M | -89.06M | -54.50M |
| OperatingCashFlow | -87.26M | -713.97M | -415.94M | 322.95M |
| CashFlowFromContinuingOperatingActivities | -87.26M | -713.97M | -415.94M | 322.95M |
| ChangeInWorkingCapital | 48.48M | -376.84M | -361.15M | 1.73B |
| ChangeInOtherWorkingCapital | 67.11M | 350.87M | -1.05B | 1.33B |
| ChangeInPayablesAndAccruedExpense | -385.63M | -378.81M | 913.40M | 600.33M |
| ChangeInPayable | -385.63M | -378.81M | 913.40M | 600.33M |
| ChangeInAccountPayable | -385.63M | -378.81M | 913.40M | 600.33M |
| ChangeInInventory | 12.91M | -74.46M | -477.80M | -8.87M |
| ChangeInReceivables | 354.09M | -274.44M | 249.17M | -183.39M |
| ChangesInAccountReceivables | 354.09M | -274.44M | 249.17M | -183.39M |
| OtherNonCashItems | -18.05M | -929.00K | -3.80M | 136.79M |
| StockBasedCompensation | 48.15M | 85.36M | 130.30M | 183.63M |
| ProvisionandWriteOffofAssets | 20.97M | 72.20M | 447.60M | 0.00 |
| AssetImpairmentCharge | 4.13M | 10.08M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 48.50M | 41.23M | 29.05M | 12.66M |
| DepreciationAndAmortization | 48.50M | 41.23M | 29.05M | 12.66M |
| OperatingGainsLosses | -51.95M | |||
| NetIncomeFromContinuingOperations | -187.50M | -545.06M | -657.94M | -1.74B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NVAX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|